ArticleFrontiers in cell and developmental biology2025

Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.

Lili Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.